KR101529334B1 - 엔도시알린의 리간드에 대한 결합을 억제하는 방법 - Google Patents

엔도시알린의 리간드에 대한 결합을 억제하는 방법 Download PDF

Info

Publication number
KR101529334B1
KR101529334B1 KR1020097023061A KR20097023061A KR101529334B1 KR 101529334 B1 KR101529334 B1 KR 101529334B1 KR 1020097023061 A KR1020097023061 A KR 1020097023061A KR 20097023061 A KR20097023061 A KR 20097023061A KR 101529334 B1 KR101529334 B1 KR 101529334B1
Authority
KR
South Korea
Prior art keywords
thr
pro
ser
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097023061A
Other languages
English (en)
Korean (ko)
Other versions
KR20100016221A (ko
Inventor
유홍 주
브라이언 이. 톰코윅
루이기 그라소
필립 엠. 사스
니콜라스 씨. 니콜레이디스
Original Assignee
모르포테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포테크, 인크. filed Critical 모르포테크, 인크.
Publication of KR20100016221A publication Critical patent/KR20100016221A/ko
Application granted granted Critical
Publication of KR101529334B1 publication Critical patent/KR101529334B1/ko
Assigned to 에이자이 아이엔씨. reassignment 에이자이 아이엔씨. 권리의 전부이전등록 Assignors: 모르포테크, 인크.
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020097023061A 2007-04-05 2008-04-04 엔도시알린의 리간드에 대한 결합을 억제하는 방법 Expired - Fee Related KR101529334B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91036207P 2007-04-05 2007-04-05
US60/910,362 2007-04-05
US98002607P 2007-10-15 2007-10-15
US60/980,026 2007-10-15
PCT/US2008/059374 WO2008124570A1 (en) 2007-04-05 2008-04-04 Methods for inhibiting the binding of endosialin to ligands

Publications (2)

Publication Number Publication Date
KR20100016221A KR20100016221A (ko) 2010-02-12
KR101529334B1 true KR101529334B1 (ko) 2015-06-16

Family

ID=39714208

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097023061A Expired - Fee Related KR101529334B1 (ko) 2007-04-05 2008-04-04 엔도시알린의 리간드에 대한 결합을 억제하는 방법

Country Status (20)

Country Link
US (4) US7807382B2 (https=)
EP (2) EP2137217B1 (https=)
JP (2) JP5825784B2 (https=)
KR (1) KR101529334B1 (https=)
CN (1) CN101918446B (https=)
AU (1) AU2008237296B2 (https=)
BR (1) BRPI0809665B8 (https=)
CA (1) CA2682726C (https=)
CY (2) CY1115370T1 (https=)
DK (2) DK2137217T3 (https=)
ES (2) ES2606906T3 (https=)
HR (2) HRP20140266T1 (https=)
HU (1) HUE031269T2 (https=)
LT (1) LT2620451T (https=)
MX (1) MX2009010701A (https=)
PL (2) PL2620451T3 (https=)
PT (2) PT2620451T (https=)
RS (2) RS53362B (https=)
SI (2) SI2137217T1 (https=)
WO (1) WO2008124570A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538700A (ja) * 2005-04-22 2008-11-06 モルフォテック、インク． 免疫エフェクター活性を有するエンドシアリン細胞に内部移行する抗体
SI2137217T1 (sl) * 2007-04-05 2014-07-31 Morphotek, Inc. Postopki za inhibiranje vezave endosialina na ligande
WO2009126725A1 (en) * 2008-04-09 2009-10-15 The Regents Of The University Of Michigan Method of modulating neovascularization
WO2010118203A2 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
US20130305396A1 (en) 2010-09-29 2013-11-14 Luigi Grasso Engineered human endosialin-expressing rodents
US9139656B2 (en) * 2012-03-30 2015-09-22 Morphotek, Inc. TEM-1 diagnostic antibodies
WO2013162748A1 (en) * 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
WO2014164544A1 (en) 2013-03-09 2014-10-09 Baylor College Of Medicine Vascular-targeted t-cell therapy
GB201702926D0 (en) * 2017-02-23 2017-04-12 Univ Birmingham Modulators
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CN110531077B (zh) * 2018-05-25 2023-07-07 荣昌生物制药(烟台)股份有限公司 间皮素免疫组化检测试剂盒
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113840825A (zh) 2019-04-01 2021-12-24 应用治疗公司 醛糖还原酶抑制剂
WO2020227430A1 (en) 2019-05-07 2020-11-12 University Of Miami Treatment and detection of inherited neuropathies and associated disorders
CN111026023A (zh) * 2020-01-12 2020-04-17 安徽楚江科技新材料股份有限公司 基于s7-400控制系统的铜带轧机PLC组态方法
CN116790744B (zh) * 2023-06-30 2024-04-26 浙江大学 一种缺血性心脏病晚期纤维化干预靶点及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391302B1 (en) * 1994-03-08 2002-05-21 Ludwig Institute For Cancer Research Method for treating cancers which present antigen FB5 with humanized antibodies

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5342757A (en) * 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
JP4122050B2 (ja) * 1993-02-05 2008-07-23 イージェニックス，インク． ヒト癌腫抗原（ｈｃａ）、ｈｃａ抗体、ｈｃａ免疫アッセイ法、画像化の方法及び治療
DE19541844C1 (de) * 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6146894A (en) * 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
WO2000013575A1 (en) 1998-09-09 2000-03-16 U.S. Army Institute Of Surgical Research Method for monitoring arterial oxygen saturation
AU2001248352A1 (en) * 2000-03-15 2001-09-24 Epigenomics Ag Diagnosis of diseases associated with the cell cycle
CA2416732C (en) 2000-08-02 2016-02-09 Brad St. Croix Endothelial cell expression patterns
ATE501635T1 (de) 2001-01-15 2011-04-15 Morphotek Inc Chemische hemmstoffe des mismatch-repair
US20040043928A1 (en) * 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040014058A1 (en) * 2001-10-05 2004-01-22 Alsobrook John P. Novel human proteins, polynucleotides encoding them and methods of using the same
EP2236614A3 (en) * 2002-08-15 2011-01-26 Genzyme Corporation Brain endothelial cell expression patterns
US20040253606A1 (en) * 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004078942A2 (en) * 2003-03-04 2004-09-16 Kirin Beer Kabushiki Kaisha Endothelial cell specific antibodies and uses thereof
WO2005086713A2 (en) * 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis
WO2006017759A2 (en) 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
WO2006029045A2 (en) 2004-09-03 2006-03-16 Kirin Brewery Co., Ltd. Endothelial cell specific antibodies and uses thereof
JP2008513533A (ja) * 2004-09-23 2008-05-01 ゲルベ Ｃｅｓｔイメージング用の造影剤封入システム
AU2005311660B2 (en) 2004-12-03 2011-07-07 Morphotek, Inc. Use of endosialin binding proteins to isolate endosialin positive cells
EP1856278A2 (en) * 2005-02-10 2007-11-21 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
JP2008538700A (ja) * 2005-04-22 2008-11-06 モルフォテック、インク． 免疫エフェクター活性を有するエンドシアリン細胞に内部移行する抗体
US7315372B1 (en) * 2005-09-29 2008-01-01 The United States Of America As Represented By The Secretary Of The Navy Instrument using near-field intensity correlation measurements for characterizing scattering of light by suspensions
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US7908090B2 (en) * 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
US20070141066A1 (en) * 2005-12-16 2007-06-21 Genentech, Inc. Method for Diagnosing, Prognosing and Treating Glioma
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
US20090239223A1 (en) * 2006-07-13 2009-09-24 Siemens Healthcare Diagnostics Inc. Prediction of Breast Cancer Response to Taxane-Based Chemotherapy
US20090176656A1 (en) * 2006-07-21 2009-07-09 Halloran Philip F Tissue rejection
ES2421354T3 (es) 2006-08-11 2013-08-30 Johns Hopkins University Secuencias consenso codificantes de cánceres de mama y colorrectales humanos
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
WO2008063479A2 (en) * 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
US20110119776A1 (en) 2007-02-05 2011-05-19 Wong Kwok-Kin Methods of diagnosing and prognosing lung cancer
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
EP1986010A1 (en) 2007-04-05 2008-10-29 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and tools for discriminating colorectal adenomas and adenocarcinomas
SI2137217T1 (sl) * 2007-04-05 2014-07-31 Morphotek, Inc. Postopki za inhibiranje vezave endosialina na ligande
JP5769417B2 (ja) 2007-08-16 2015-08-26 ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ 腫瘍細胞由来微小胞
EP2245199B1 (en) * 2008-02-01 2013-11-13 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
US20110117551A1 (en) 2008-02-19 2011-05-19 Oncomethylome Sciences Sa Detection and prognosis of lung cancer
US20110117111A1 (en) 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20110256560A1 (en) 2008-10-20 2011-10-20 University Health Network Methods and compositions for the detection of ovarian cancer
CA2749601C (en) 2009-01-14 2020-07-21 Stephen M. Hewitt Ratio based biomarkers and methods of use thereof
WO2010118203A2 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391302B1 (en) * 1994-03-08 2002-05-21 Ludwig Institute For Cancer Research Method for treating cancers which present antigen FB5 with humanized antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Immun., Vol. 6, No. 10 (2006.07.31.) *
Cancer Immun., Vol. 6, No. 10 (2006.07.31.)*

Also Published As

Publication number Publication date
AU2008237296A1 (en) 2008-10-16
CA2682726A1 (en) 2008-10-16
DK2620451T3 (da) 2017-01-02
BRPI0809665B1 (pt) 2021-03-23
RS53362B (sr) 2014-10-31
JP2013150618A (ja) 2013-08-08
US9505842B2 (en) 2016-11-29
HRP20140266T1 (hr) 2014-04-25
AU2008237296B2 (en) 2013-07-04
PT2620451T (pt) 2016-12-20
SI2620451T1 (sl) 2017-01-31
CN101918446B (zh) 2014-06-18
JP2010523592A (ja) 2010-07-15
JP5825784B2 (ja) 2015-12-02
MX2009010701A (es) 2010-01-20
US20110033455A1 (en) 2011-02-10
PL2137217T3 (pl) 2014-08-29
WO2008124570A8 (en) 2008-11-27
BRPI0809665B8 (pt) 2021-05-25
ES2606906T3 (es) 2017-03-28
CN101918446A (zh) 2010-12-15
US8895000B2 (en) 2014-11-25
US20150079104A1 (en) 2015-03-19
CY1115370T1 (el) 2017-01-04
RS55447B1 (sr) 2017-04-28
EP2137217B1 (en) 2014-03-05
EP2137217A1 (en) 2009-12-30
PT2137217E (pt) 2014-03-20
KR20100016221A (ko) 2010-02-12
EP2620451A1 (en) 2013-07-31
US7807382B2 (en) 2010-10-05
ES2452929T3 (es) 2014-04-03
US20170029509A1 (en) 2017-02-02
BRPI0809665A2 (en) 2018-12-04
CY1118592T1 (el) 2017-07-12
LT2620451T (lt) 2017-01-10
EP2620451B1 (en) 2016-09-14
SI2137217T1 (sl) 2014-07-31
WO2008124570A1 (en) 2008-10-16
HRP20161715T1 (hr) 2017-02-10
PL2620451T3 (pl) 2017-06-30
US20080248034A1 (en) 2008-10-09
DK2137217T3 (en) 2014-03-17
CA2682726C (en) 2017-05-09
HUE031269T2 (en) 2017-06-28
US10053509B2 (en) 2018-08-21

Similar Documents

Publication Publication Date Title
KR101529334B1 (ko) 엔도시알린의 리간드에 대한 결합을 억제하는 방법
US12319741B2 (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
JP6087503B2 (ja) ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途
CN109793893B (zh) 用于诊断和治疗癌症的vista调节剂
KR20200035291A (ko) 인터류킨-21 뮤테인 및 치료 방법
KR20150023811A (ko) 암의 치료를 위한 lsr 항체 및 그의 용도
JP2012031172A (ja) Ｔ細胞阻害性受容体組成物およびその使用
CN101189264A (zh) M-csf特异性单克隆抗体及其应用
KR20200044899A (ko) 암의 치료 및 진단을 위한 tim-3 길항제
KR20130108430A (ko) 항-노치1 항체
TW200823235A (en) Prophylactic and therapeutic agent for cancers
KR20200109339A (ko) Tim3에 대한 항체를 사용하여 암을 치료하는 방법
TW202426504A (zh) Lilrb2抗體產品及方法
KR20120078725A (ko) 세포 외 기질 단백질의 아미노산 서열 ｒｇｄ에 특이적인 인간화된 항체 및 그의 용도
CN101316861A (zh) Il-17a和il-17f拮抗剂以及使用所述拮抗剂的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180528

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20190530

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250611

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250611

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250611